AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04385745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodegradable Intramedullary Nailing (BIN)
Description: Unstable forearm shaft fractures are treated by the study method (BIN) or the control method (ESIN).
Study NCT04129255 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Octreotide Acetate
Description: administration every 28 days
Study NCT00972231 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Summary
Description: Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.
Study NCT01274962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: * Oxaliplatin\* 85 mg/m2 IV in 500 mL of D5W over 120 minutes~* Folinic Acid (Leucovorin)\* 400 mg/m2 IV in 250 ml D5W over 120 minutes~* 5-Fluorouracil (5-FU) 400 mg/m2 IV bolus, after Folinic Acid~* 5-Fluorouracil\*\* 2400 mg/m2 IV over 46 h in D5W to a total volume of 92 mL by continuous infusion at 2 mL/hour.~* Repeat every 14 days for 6 cycles in the arm A and to be completed with 6 cycles after surgery and 12 cycles in arm B.~If necessary the schedule may be modified +/- 3 days.
Study NCT01274962 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: high dose rate endorectal brachytherapy
Description: High dose rate endorectal brachytherapy, consisting in a total dose of 26 Gy in 4 daily fractions of 6.5 Gy.
Study NCT02119052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octeotride
Study NCT02119052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04436718 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Daily pocus exam
Description: Daily evaluation of lung ultrasound for B line artifacts plus IVC assessments
Study NCT03368391 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tetracaine HCl and oxymetazoline HCL
Description: 0.4 mL HCl and oxymetazoline HCl administered intranasally
Study NCT03521167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intraoperatively use. start dexmedetomidine infusion at 0.5 mcg/kg/min after anesthesia induction, and continue up to 1 hour prior to extubation.
Study NCT03521167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: Postoperatively use. 300 mg PO TID starting POD1 until discharge Use lower dose for >65y or if patient having significant sedation/dizziness
Study NCT03521167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Postoperatively use. 300 mg PO TID starting POD1 until discharge Use lower dose for >65y or if patient having significant sedation/dizziness
Study NCT03521167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tylenol
Description: Postoperatively use. 1000 mg PO Q8hr starting POD0 until discharge (max 3000 mg in 24hrs) Reduce to 650 mg PO Q6h if \<70kg
Study NCT03521167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol
Description: Postoperatively use. 1000 mg PO Q8hr starting POD0 until discharge (max 3000 mg in 24hrs) Reduce to 650 mg PO Q6h if \<70kg
Study NCT03521167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin Pill
Description: Pre-operatively use. 300mg PO up to 1 hour before OR time Reduce to 100 mg PO in patients >65y or with GFR \< 50 Consider dose reduction in patients with sleep apnea
Study NCT03521167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin Pill
Description: Pre-operatively use. 300mg PO up to 1 hour before OR time Reduce to 100 mg PO in patients >65y or with GFR \< 50 Consider dose reduction in patients with sleep apnea
Study NCT03521167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tylenol Pill
Description: Pre-operatively use. 1000 mg PO up to 1 hour before OR time Reduce to 650 mg PO if \<70kg Don't use if h/o liver disease or anticipated liver injury (right heart failure, pulmonary hypertension, etc leading to systemic venous congestion)
Study NCT03521167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol Pill
Description: Pre-operatively use. 1000 mg PO up to 1 hour before OR time Reduce to 650 mg PO if \<70kg Don't use if h/o liver disease or anticipated liver injury (right heart failure, pulmonary hypertension, etc leading to systemic venous congestion)
Study NCT03641469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green Sun Dynamic Brace
Description: Change from standard-of-care TLSO to GSM brace
Study NCT01880268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI-controlled neurorehabilitation device
Description: Brain computer interface (BCI) -controlled neurorehabilitation device uses a participant's EEG to control with movements of an ordinary rehabilitation device (an upper limb ergometry, arm bike)
Study NCT01880268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation therapy
Description: Standard rehabilitation therapy for patient with stroke includes 1 hour of physical therapy and 1 hour of occupational therapy
Study NCT03368391 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 2% Lidocaine with 1:100,000 epinephrine
Description: 2.5 mL of 2% Lidocaine with 1:100,000 epi will be infiltrated at anterior teeth
Study NCT03368391 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 3% Mepivacaine with 1:100,000 epinephrine
Description: 2.5 mL of 3% Mepivacaine will be infiltrated at anterior teeth
Study NCT03368391 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: saline intranasal
Description: 0.4 mL intranasal saline will be administered as a placebo
Study NCT03368391 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: saline infiltration
Description: 2.8 mL of saline will be infiltrated at anterior teeth as a placebo
Study NCT00622362 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DEPIGOID Dermatophagoides pteronyssinus
Description: Subcutaneous administration:0.5 ml/month during 1 year
Study NCT00622362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polymerized TOL of Dermatophagoides pteronyssinus
Description: Sublingual immunotherapy. Two drops daily during 1 year
Study NCT00622362 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Sublingual immunotherapy. Two drops daily during 1 year
Study NCT00752076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cancer cell lines establishment
Description: Detection of epithelial growth factor receptor (EGFR) mutation in malignant pleural effusion of lung cancer patients and cancer cell lines establishment
Study NCT02414464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide
Description: Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP 35% gel was applied to the vestibular faces of these teeth.~In the present study, the Whiteness HP 35% gel was applied without an external auxiliary source. As this is not a self-catalyzed system, the gel was removed after each 15-minute application and reapplied two more times, totaling 45 minutes of contact with the teeth.
Study NCT02414464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide
Description: Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 35% gel was applied to the vestibular faces of these teeth for 40 minutes in each session.
Study NCT02414464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% hydrogen peroxide
Description: Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 20% gel was applied to the vestibular faces of these teeth 50 minutes in each session.
Study NCT02748174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Files
Description: Patients will be given a link to download audio files. They consist of breathing techniques, imaging, progressive relaxation, and more. Patients will be asked to perform 20 minutes of relaxation therapy at least 3 times per week. Patients will record their headache frequency and intensivy, in addition to other symptoms, and the frequency of practiving the behavioral therapy using Curelator Headache.
Study NCT02189967 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional fractionation
Description: In this treatment arm patients will receive radiotherapy with the currently used conventional fractionation schedule i.e. 5 fractions per week, 2 Gy single dose.
Study NCT02189967 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: accelerated fraction
Description: In this treatment arm patients will receive radiotherapy with an accelerated fractionation schedule i.e. 7 fractions per week, 2 Gy single dose.
Study NCT00619242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 2 tablets with water by mouth twice a day for two weeks.
Study NCT03241550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazonium sulfate - intravenous
Description: IV infusion
Study NCT04037254 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gonadotrophin Releasing Hormone
Description: Receive standard of care GnRH agonist androgen suppression therapy
Study NCT03241550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazonium sulfate - oral
Description: Oral
Study NCT04037254 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotrophin Releasing Hormone
Description: Receive standard of care GnRH agonist androgen suppression therapy
Study NCT04037254 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo standard of care IMRT
Study NCT04037254 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo standard of care IMRT
Study NCT04037254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO
Study NCT02477943 — intervention group
Intervention type: DEVICE
Intervention: Advanced MRI Neuroimaging
Description: Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
Study NCT02180711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Study NCT02180711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab (IV)
Study NCT02180711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT03067467 — intervention group
Intervention type: DRUG
Intervention: Hyperpolarized 13C-Pyruvate
Description: Hyperpolarized 13C-pyruvate IV bolus followed by brain MRSI.
Study NCT03067467 — intervention group
Intervention type: DRUG
Intervention: Gadolinium
Description: Brain MRI performed with and without gadolinium-based contrast.
Study NCT01142999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunflower oil
Description: One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
Study NCT06642779 — intervention group
Intervention type: BEHAVIORAL
Intervention: VFQ- 25 (Visual Function Questionnaire)
Description: VFQ-25 questionnaire was used to evaluate patient satisfaction at the M3 and M12 visits.
Study NCT01142999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.
Study NCT01590199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Study NCT01590199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230
Study NCT03269955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen/thrombin-coated collagen patch
Description: Tachosil® is cut in half and applied to the front and back of the pancreaticojejunostomy respectively, and fibrin glue is applied on it
Study NCT02881359 — intervention group
Intervention type: DEVICE
Intervention: LifeSeal® Kit
Description: used as an adjunct to suture or staple line during standard surgical repair of the GI tract (anastomosis or linear) to provide re-inforcement and help reduce leaks.
Study NCT01702415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Single dose, intravenous solution 5mg
Study NCT01702415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00681473 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation Therapy
Description: Once daily, Monday through Friday, for 6 weeks.
Study NCT02681588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Obstetric management
Description: Screening for gestational diabetes at 32 weeks of gestation, determination of fasting glucose during late pregnancy ; blood samples on arrival at the delivery room ; drawing blood from the umbilical cord after section; skinfold measurement of the newborn within 72 hours of life.
Study NCT02681588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Obstetric management
Description: Screening for gestational diabetes at 32 weeks of gestation, determination of fasting glucose during late pregnancy ; blood samples on arrival at the delivery room ; drawing blood from the umbilical cord after section; skinfold measurement of the newborn within 72 hours of life.
Study NCT02208973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-680
Description: 5, 10, 20, 40 and 60 mg of PBF-680
Study NCT06642779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Biometry
Description: Axial length, anterior chamber depth and corneal keratometric values K1-K2. All these parameters were measured at the screening visit and at the month 3 follow-up visit, using the ARGOS® Biometer or the ANTERION® Cataract App
Study NCT03791983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scalp Acupuncture
Description: Scalp acupuncture is a form of alternative medicine in which thin needles are inserted into the scalp. It is a key component of traditional Chinese medicine (TCM).
Study NCT03791983 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Body Acupenture
Description: Acupuncture is a form of alternative medicine in which thin needles are inserted into the body. It is a key component of traditional Chinese medicine (TCM).
Study NCT06642779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Slit lamps / Fundoscopy / Biomicroscopy
Description: The fundus and other ocular structures, such as the cornea, anterior chamber, iris, pupil, crystalline lens / IOL alignment, corpus ciliare and choroid were examined at screening visit, on the day of the surgery, and at the follow up visits D1, M1, M3, M6, and M12, using the slit lamp binocular indirect ophthalmoscopy.
Study NCT01670630 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sheathed speculum examination
Study NCT01670630 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard speculum examination
Study NCT04548999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (body weight \<75 kg) or 1800 mg (body weight ≥ 75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion Q24W.~During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total)
Study NCT04548999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered at a dose of 600 mg Q24W. The first dose of ocrelizumab will be administered as two 300 mg, IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion Q24W.
Study NCT04548999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihistamine
Description: Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
Study NCT04548999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
Study NCT04548999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
Study NCT04548999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
Study NCT04420455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoximone
Description: Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval.
Study NCT01024465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReShape Duo Balloon
Description: ReShape Duo Balloon
Study NCT02208973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for the dose of 5, 10, 20 and 40 mg of PBF-680
Study NCT03995550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 142397
Description: A compound in development by LEO Pharma A/S
Study NCT03995550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04411173 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein
Description: Each condition (both rice and whey protein) match in color, flavor, and serving size.
Study NCT06642779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: UDVA
Description: Monocular and binocular Uncorrected Distance Visual Acuity (UDVA) was evaluated at all visits (preoperative, D1, M1, M3, M6 and M12), using the ETDRS chart.
Study NCT03304821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Participants will self-administer 500 μg/day of GM-CSF, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of subcutaneous GM-CSF, three times per week for another 3 weeks and then will be followed for another 3 months.
Study NCT03304821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will self-administer 500 μg/day of a placebo, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of a placebo administered subcutaneously, three times per week for another 3 weeks and then will be followed for another 3 months.
Study NCT01142999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aquaphor ointment
Description: One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
Study NCT01142999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetaphil cream
Description: One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
Study NCT03717311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: The intervention will be done on 1 day, time during which, each subject will stay at the CRNH. A breakfast containing the fibers will be given to them, then during 24h a following will be done to get fecal, urinary, plasmatic and expiratory samples. Standardized lunch, dinner and collation will be served during the day.
Study NCT02040233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAY1067197 (10 mg)
Description: 10 mg BAY1067197 for 7 d treatment once daily as oral application
Study NCT02040233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAY1067197
Description: The dose escalation to the second dose step will proceed only if the previous dose step has shown acceptable safety and tolerability 5 mg / or 10 mg / or 20 mg BAY1067197 for 7 d treatment as oral application.
Study NCT02040233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (10 mg)
Description: 10 mg Placebo for 7 d treatment once daily as oral application